Category: pyrrolines

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55750-49-7,Ethyl 2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate,as a common compound, the synthetic route is as follows.

55750-49-7, b) N-(tert.butyloxycarbonyl)-5-(N-maleinimido)pentylamine 13.1 g (50 mmol) of the compound prepared according to Example 1b is dissolved in 250 ml saturated sodium carbonate solution. The solution is filtered over a folded filter and cooled to 0 C. 8.4 g (50 mmol) N-(ethoxycarbonyl)-maleinimide is added while stirring and is left to stir for a further 15 min at room temperature, during which the N-(ethoxycarbonyl)-maleinimide dissolves completely after a short time. Subsequently 400 ml tetrahydrofuran is added together with 250 ml saturated sodium carbonate solution and it is allowed to react for a further 1 h. The solution is then extracted with 2*500 ml acetic ester, the extract is washed with 500 ml water and dried with 50 g Na2 SO4. After evaporation in a rotary evaporator the product is obtained as a viscous oil which is dried in a high vacuum. Yield: 9.6 g (corresponds to 68% of the theoretical yield). TLC: silica gel, n-butanol/glacial acetic acid/water 40/10/50 (v/v/v), spray with 0.1% KMnO4 solution; Rf =0.85.

The synthetic route of 55750-49-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Boehringer Mannheim GmbH; US5595741; (1997); A;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

(e) N-((S)- 1-(((S)- 1-((4-((S)-8-(3-(((S)-2-(Benzo[d][1, 3]dioxol-5-yl)-7-methoxy-5-oxo-5, 11a- dihydro-1H-pyrrolo[2, 1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-7-methoxy-5-oxo-5, 11a- dihydro-1H-pyrrolo[2, 1-c][1,4]benzodiazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3- methyl- 1 -oxobutan-2-yl)- 1-(3-(2, 5-dioxo-2, 5-di hydro- 1H-pyrrol- 1 -yl)propanamido)- 3,6,9, 12, 15, 18,21 ,24-octaoxaheptacosan-27-amide (33) The imine 32 (92 mg, 0.1 mmol, 1.1 equiv.) was dissolved in CHCI3 (6 mL) with one drop of anhydrous MeOH to aid dissolution. Maleimide-PEG8-acid (53 mg, 0.09 mmol, 1 equiv.) was added followed by EEDQ (33 mg, 0.14 mmol, 1 .5 equiv.). This was left to stir vigorously at room temperature under Ar for 4 days until LC/MS analysis showed majority product formation. The solvent was removed in vacuo and the crude product was partially purified by silica gel column chromatography (CHCI3 with 1 % to 10% MeOH gradient) yielding 33 (81 mg). The material was purified further by preparative HPLC to give 33 as a yellow solid (26.3 mg, 18%). Fast Formic run: LC/MS (1.39 min (ES+) m/z (relative intensity) 1485.00 ([M + H]+., 64).

1334177-86-4, 1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various.

Reference£º
Patent; SPIROGEN SARL; HOWARD, Philip Wilson; WO2014/57073; (2014); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

69778-83-2, 4-Methoxy-1H-pyrrol-2(5H)-one is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 1 Compound (VII) To a solution of 2-formyl-5-undecylpyrrole (4 g; 16.03 mmols) and 4-methoxy-3-pyrrolin-2-one (3.63 g; 32.06 mmols) in DMSO (53 ml) 2N sodium hydroxyde (45 ml) is added under nitrogen atmosphere and the mixture is stirred at 60¡ã C. for 8 hours. After dilution with water (200 ml) the yellow suspension is extracted with dichloromethane (600 ml). The organic phase is shacked with water and brine, anhydrified over anhydrous sodium sulphate and evaporated to dryness. The crude material is taken up in hexane and filtered to give 4-methoxy-5-(5-undecyl-1H-pyrrol-2-yl-methylene)-1,5-dihydro-pyrrol-2-one (4.86 g; 14.11 mmols) as a yellow crystalline solid. Yield: 88percent. 1 NMR (400 mhz, CDCl3), ppm: 0.87 (3H, m), 1.2-1.5 (16H, m), 1.72 (2H, m), 2.73 (2H, m), 3.89 (3H, s), 5.08 (1H, d, J=1.7 Hz), 5.97 (1H, dd, J=2.4 and 3.2 Hz), 6.31 (1H, s), 6.36 (1H, t, J=3.2 Hz), 10.25 (1H, bs), 10.74 (1H, bs)., 69778-83-2

The synthetic route of 69778-83-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Pharmacia & UpJohn S.p.A.; US5847127; (1998); A;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25021-08-3,2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

tert-Butyl 1-amino-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oate (100 mg, 201 mumol) was initially charged in 1.0 ml of DMF, and (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid (46.8 mg, 301 mumol), 1-hydroxy-1H-benzotriazole hydrate (76.9 mg, 502 mumol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (77.0 mg, 402 mumol) were added. The reaction mixture was stirred at RT overnight, and ethyl acetate was then added. The organic phase was washed twice with 5% citric acid solution, with saturated sodium hydrogencarbonate solution and once with saturated sodium chloride solution. The organic phase was dried over magnesium sulphate. The solvents were evaporated under reduced pressure and the residue was purified by preparative RP-HPLC (column: Reprosil 125*30; 10mu, flow rate: 50 ml/min, MeCN/water/0.1% TFA). The solvents were evaporated under reduced pressure and the residue was dried under high vacuum. This gave 19.1 mg (13% of theory) of tert-butyl 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-oxo-6,9,12,15,18,21,24,27-octaoxa-3-azatriacontan-30-oate. LC-MS (Method 1): Rt=0.87 min; MS (ESIpos): m/z=635 [M+H]+, 25021-08-3

As the paragraph descriping shows that 25021-08-3 is playing an increasingly important role.

Reference£º
Patent; Bayer Pharma Aktiengesellschaft; LERCHEN, Hans-Georg; REBSTOCK, Anne-Sophie; CANCHO GRANDE, Yolanda; MARX, Leo; STELTE-LUDWIG, Beatrix; TERJUNG, Carsten; MAHLERT, Christoph; GREVEN, Simone; SOMMER, Anette; BERNDT, Sandra; (684 pag.)US2018/169256; (2018); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EDCI.HCI (0.13 g, 0.66 mmol, 1.1 eq.) was added to a cloudy solution of compound 21(0.61 g, 0.6 mmol, 1.0 eq.) and Mal-dPEG8-OH (0.393 g, 0.66 mmol, 1.1 eq.) in CHCI3(25 mL). The clear solution was stirred at room temperature for 1 .5h., diluted with CHCI3(100 mL) washed with brine (2 x 100 mL), dried (Mg504) and evaporated under reducedpressure to give a yellow foam. Purification by flash column chromatography [CHCI3/MeOH0% to 6% in 1% increments gave the product as a white foam (0.786 g, 82%). AnalyticalData: RT 1.44 mm; MS (ES) m/z (relative intensity) 1586 ([M + H],40), 1609 ([M + Na],100)

1334177-86-4, The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ADC THERAPEUTICS SA; MEDIMMUNE LIMITED; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; DUNNY, Elizabeth; HUTCHINSON, Ian; MASTERSON, Luke; (73 pag.)WO2017/137556; (2017); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

25021-08-3, 2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Trifluoroacetic Acid/(2S)-2-amino-4-[{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}(glycoloyl)amino]-N-{2-[(2-{[(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetyl]amino}ethyl)sulphonyl]ethyl}butanamide (1:1) The title compound was prepared from Intermediate L81 by coupling with Intermediate C58 in the presence of HATU and N,N-diisopropylethylamine. In the next step, the Z protective group was removed by hydrogenation over 10% palladium on activated carbon in DCM/methanol 1:1 at RT under hydrogen standard pressure for 30 min. The deprotected intermediate was then converted by coupling with (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid in the presence of HATU and N,N-diisopropylethylamine and finally by deprotection with zinc chloride into the title compound. LC-MS (Method 1): Rt=0.83 min; MS (ESIpos): m/z=785 (M+H)+.

25021-08-3, The synthetic route of 25021-08-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Bayer Pharma Aktiengesellschaft; LERCHEN, Hans-Georg; REBSTOCK, Anne-Sophie; CANCHO GRANDE, Yolanda; MARX, Leo; STELTE-LUDWIG, Beatrix; TERJUNG, Carsten; MAHLERT, Christoph; GREVEN, Simone; SOMMER, Anette; BERNDT, Sandra; (684 pag.)US2018/169256; (2018); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

N-(3-Dimethylaminopropyl)-N?-ethylcarbodiimide (28 mg, 0.146 mmol, I eq) was added to asolution of 42 (203 mg, 0.146 mmol) and maleimide-PEG8 acid (87 mg, 0.146 mmol) inchloroform (5 mL). The reaction was stirred for 1.5 h then diluted with chloroform (50 mL), washed with water (50 mL), brine (30 mL), dried over magnesium sulphate, filtered and evaporated. Flash chromatography [gradient elution 100% DCM to 90% DCM/I0% methanol] gave 43 as a pale yellow solid (205 mg, 72%). LC/MS: RT 5.75 mm; MS (ES+)m/z (relative intensity) 982.90 (100), 1963.70 (5)., 1334177-86-4

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52532; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

134272-64-3, N-(2-Aminoethyl)maleimide Hydrochloride is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

GA16OH was used for the synthesis of GA16-MA to increase the solubility in hydrocarbon. To asolution of GA16OH (0.5g, 0.60mmol) in dichloromethane (10 mL) was added N,Ndiisopropylethylamine(0.85ml, 6mmol). The mixture was treated with N-(3-dimethylaminopropyl)-N?-ethylcarbodiimide hydrochloride (0.19g, 1mmol), 1-hydroxybenzotriazole (0.13g, 1mmol) and N-(2-aminoethyl)maleimide hydrochloride (0.116g,0.66mmol) and stirred at room temperature overnight. The reaction was quenched with droplet ofHCl (1M) solution and washed with water for three times. The organic portion was dried overNa2SO4. The crude material was purified by silica gel column chromatography using hexane andEtOAc (4/1 to 3/1).1H NMR (400MHz, CDCl3): delta 6.96 (s, 2H), 6.73 (s, 2H), 6.58 (t, J=4.6 Hz, 1H), 4.04-3.96 (m,6H), 3.84-3.82 (m, 2H), 3.66-3.62 (m, 2H), 1.83-1.71 (m, 6H), 1.49-1.45 (m, 6H), 1.37-1.26 (m,72H), 0.90-0.86 (m, 9H)HRMS (ESI): Calculated for C61H108N2O6 ([M+H]+): 965.8286 , found 965.8264.

134272-64-3, The synthetic route of 134272-64-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Zhang, Qifan; Scigliano, Anita; Biver, Tarita; Pucci, Andrea; Swager, Timothy M.; Bioorganic and Medicinal Chemistry; (2018); p. 5307 – 5313;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

DCM (10.00 ml) and methanol (0.4 ml) were added to 36 (393 mg, 0.305 mmol), followed by mal-amido-peg8-acid (380 mg, 0.628 mmol, 2.06 eq) and EDCI (128 mg, 0.668 mmol, 2.2 eq). The reaction was allowed to proceed at room temperature for 4h when completion 15 was observed by LCMS. Ammonium chloride in water (30 ml, 6 mass%) was added and the mixture was stirred vigorously. The mixture was decanted in a biotage phase separation cartridge. The DCM layer was evaporated to dryness under vacuum and the crude residue was purified by chromatography (25g Ultra gradient 15/85 to 100/0 of 20% MeOH in DCM I DCM in 12CV; hold at elution around 48%). The fractions were analysed 20 by TLC (1 0% MeOH in DCM). The pure fractions were pooled. The solvent was removed by evaporation. The residue was purified further by reverse phase preparative HPLC (gradient 15 to 75% water/acetonitrile + 0.01% formic acid) followed by freeze-drying and aliquoted from DCM to give 37 (516 mg, 0.212 mmol, 69.4% Yield) as a white foam. The purity was 97.65%. Analytical Data: LC/MS, 15 min method, RT 6.61 min; MS (ES+) m/z 25 (relative intensity) 1219.7 ([M + 2Hf+¡¤, 100); 1H NMR (400 MHz, DMSO-d6) o 9.92 (s, 2H), 8.17 (d, J = 6.9 Hz, 2H), 8.01 (t, J = 5.6 Hz, 2H), 7.87 (d, J = 8.7 Hz, 2H), 7.72- 7.44 (m, 4H), 7.39- 7.10 (m, 4H), 7.05 (s, 2H), 7.00 (s, 4H), 6.76 (s, 2H), 6.66- 6.46 (m, 2H), 5.56 (d, J = 7.1 Hz, 2H), 5.34 (dd, J = 9.7, 5.9 Hz, 2H), 5.21 – 4.70 (m, 4H), 4.39 (t, J = 7.0 Hz, 2H), 4.22 (dd, J = 8.7, 6.7 Hz, 2H), 4.15-4.01 (m, 2H), 3.94 (d, J = 15.3 Hz, 4H), 3.8630 3.72 (m, 8H), 3.60 (t, J = 7.3 Hz, 8H), 3.55- 3.42 (m, 58H), 3.37 (t, J = 5.9 Hz, 4H), 3.15 (q, J = 5.8 Hz, 4H), 2.76-2.56 (m, 4H), 2.46 (t, J = 6.8 Hz, 2H), 2.40 (t, J = 6.5 Hz, 2H), 2.36- 2.29 (m, 4H), 1.96 (q, J = 6.7 Hz, 2H), 1.78 (s, 4H), 1.66 (d, J = 6.6 Hz, 6H), 1.57 (d, J = 8.6 Hz, 2H), 1.30 (d, J = 7.0 Hz, 6H), 0.85 (dd, J = 15.2, 6.7 Hz, 12H)., 1334177-86-4

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MEDIMMUNE LIMITED; DIMASI, Nazzareno; HOWARD, Philip Wilson; MASTERSON, Luke; TIBERGHIEN, Arnaud Charles; VIJAYAKRISHNAN, Balakumar; WHITE, Jason; (135 pag.)WO2019/34764; (2019); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

17057-04-4, 4-(2,5-Dioxo-2,5-dihydro-pyrrol-1-yl)-benzoicacid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Equimolar quantities of maleimide (2) and nitrones (5a-k and 6a-k) were refluxed in toluene (20 ml) and ethyl alcohol (5 ml) for 8-10 h (TLC monitoring using petroleum ether and hexane 1:1) followed by cooling with addition of dry ether. The products (7a-k and 8a-k) were separated out after filtration and recrystallized from toluene and petroleum ether mixture (1:1) to yield cis-isomers (7aa-7ka and 8aa-8ka). The mother liquor on further work up provided trans-isomers which were recrystallized from ethanol and diethyl ether mixture (1:1) (7aa’-7ka’ and 8aa’-8ka’) (Fig. 3).7 These stereoisomers were characterized by their 1H NMR, IR and mass spectra in addition to their melting points and elementary analysis. These stereoisomers have identical IR spectra and elemental analysis but differ in their melting points, 1H NMR and mass spectra., 17057-04-4

17057-04-4 4-(2,5-Dioxo-2,5-dihydro-pyrrol-1-yl)-benzoicacid 86925, apyrrolines compound, is more and more widely used in various.

Reference£º
Article; Anand, Preet; Singh, Baldev; Bioorganic and Medicinal Chemistry; vol. 20; 1; (2012); p. 521 – 530;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem